A Phase I/II Open Label Multi-center Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients with Advanced Malignancies

A Phase I/II Open Label Multi-center Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients with Advanced Malignancies
Recruiting
18 years - 99 years
All
Phase 1
10 participants needed
1 Location

Brief description of study

The purpose of this study is to help define the proper dose amounts, safety and benefits of AMXI-5001 in participants 18 years and older, who have the disease which the study drug may treat, for example, cancer. This study is the first time AMXI-5001 has been given to people.
We will learn the following from this study:
• How your body reacts to different dose levels of AMXI-5001
• If AMXI-5001 is useful in treating tumors with BRCA1 and BRCA2 mutations, or other mutations that are involved in cell repair
• How much and how fast AMXI-5001 gets into your blood stream and how long it takes to leave your body

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cancer,refractory cancer,advanced malignancies
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 848732

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Race
Select race of your choice
Ethnicity
Select ethinicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center